(CYTK) Cytokinetics - Ratings and Ratios

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, specializes in the discovery, development, and commercialization of muscle activators and inhibitors designed to treat severe and debilitating diseases. The company focuses on small molecule drug candidates engineered to modulate muscle function and contractility, addressing unmet medical needs in cardiovascular and neuromuscular disorders. Its pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III trials for heart failure; CK-089, a fast skeletal muscle troponin activator in Phase I; CK-586, a cardiac myosin inhibitor in Phase II; and aficamten, a novel cardiac myosin inhibitor in Phase III for hypertrophic cardiomyopathy. Cytokinetics has strategic partnerships, including a collaboration with Ji Xing Pharmaceuticals and a license agreement for aficamten in Japan. Founded in 1997, the company is headquartered in South San Francisco, California.

Ticker Symbol: CYTK Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology Average Volume 20d: 2477128 Last Price: 40.43 SMA 20: 38.74 SMA 50: 42.53 SMA 200: 50.04 ATR: 2.69 Market Cap: 4520.80M USD P/E: None P/E Forward: None P/B: 60.31 P/S: 244.71 RoE: 435.49 3 Month Forecast: Based on and , CYTK is expected to face resistance near SMA 50 (~42.53) and SMA 200 (~50.04). Support is likely at SMA 20 (~38.74). With a high ATR (2.69), volatility is expected to remain moderate. The stocks elevated P/B (60.31) and P/S (244.71) suggest limited upside unless driven by positive clinical trial results or strategic developments. Price targets: $44.00 (resistance), $37.00 (support). Stop-loss recommended below $36.00.